SS-31 vs MOTS-c: two mitochondrial peptides compared

What is SS-31?

SS-31 is a synthetic tetrapeptide from the Szeto-Schiller series, with the sequence D-Arg-Dmt-Lys-Phe-NH2. In clinical development it is called elamipretide, and it has also appeared as MTP-131 and Bendavia. Its alternating aromatic and basic residues let it cross cell membranes and gather in the inner mitochondrial membrane.

A 2014 review described SS-31 binding cardiolipin and preventing cardiolipin from converting cytochrome c into a peroxidase, while preserving electron transport. Later reviews summarised effects observed in models as stabilised cristae, less oxidative stress and higher ATP production. SS-31 is unusual among research peptides in having large randomised human trials behind it.

What is MOTS-c?

MOTS-c is a 16 amino acid peptide encoded by a short open reading frame inside the mitochondrial 12S rRNA gene. It was described in 2015 by Lee and colleagues as a mitochondrial-derived peptide whose primary target organ in mice appeared to be skeletal muscle.

In that work, MOTS-c inhibited the folate cycle and linked purine synthesis, which activated AMPK. A 2018 study reported that under metabolic stress MOTS-c moved into the nucleus and influenced the expression of stress response genes, interacting with factors such as NRF2. MOTS-c has been measured in human plasma, but the peptide itself has not been tested in controlled human trials.

How do they compare?

Mechanisms side by side

The two peptides act at different levels. SS-31 is described as working on the structure of the mitochondrion: by binding cardiolipin it was reported to help hold the respiratory complexes in place and to limit peroxidation of the membrane. Its effects in models are framed as protecting or restoring mitochondria that are already damaged.

MOTS-c is described as working on the cell's metabolic programme. Through AMPK it touches glucose handling and energy sensing, and through its move into the nucleus it was reported to change the expression of genes involved in antioxidant defence. In other words, SS-31 research asks how to keep the machinery intact, while MOTS-c research asks how mitochondria signal to the rest of the cell.

Both lines of work touch oxidative stress and NRF2. SS-31 increased NRF2 in activated macrophages in a lung fibrosis model, and MOTS-c interacted with NRF2 in the nucleus in cell studies. These are separate observations in different systems and do not show a shared pathway.

Research findings compared

• Muscle and physical capacity: MOTS-c was associated with better physical performance in young, middle aged and old mice and with less muscle loss after immobilisation. SS-31 did not improve the six minute walk test in the MMPOWER-3 trial of primary mitochondrial myopathy, but walking distance improved in the Barth syndrome extension study. Verdict: human data exist only for SS-31, and they are mixed.
• Metabolism and insulin sensitivity: MOTS-c is the stronger candidate in published work, with mouse studies of diet-induced insulin resistance and gestational diabetes and human plasma studies linking its levels to insulin sensitivity markers in lean individuals. SS-31 research has focused less on this area.
• Inflammation and fibrosis: SS-31 reduced fibrosis and IL-1beta and IL-18 in a bleomycin mouse model, and MOTS-c lowered circulating IL-1beta and IL-6 in the immobilisation model. Both findings are single studies in mice.
• Brain: SS-31 was associated with better memory performance after lipopolysaccharide exposure in mice and after isoflurane exposure in developing rats. No comparable MOTS-c brain studies are among the sources reviewed here.
• Heart: SS-31 has the clinical data, including Barth syndrome reports of improved heart function, though a 2026 review noted that an effect on heart disease remained unconfirmed. For MOTS-c, human data are limited to lower circulating levels in patients with coronary endothelial dysfunction.

Have they been studied together?

No published study that used SS-31 and MOTS-c together was found in PubMed. Reviews of each peptide mention the other only as part of the wider field of mitochondria-targeted research. Whether a structural protector and a metabolic signal would add to each other, cancel out or do nothing in combination is an open question that only a purpose-built study could answer.

Choosing between them for a study design

If the research question concerns membrane integrity, cardiolipin, oxidative injury to mitochondria or a disease model where human comparison data matter, SS-31 has the deeper record and an established clinical literature to reference. If the question concerns metabolic signalling, AMPK, insulin sensitivity in rodents or how mitochondrial DNA influences nuclear genes, MOTS-c is the more direct tool.

Practical points also differ. SS-31 is small, which simplifies analytical work such as mass spectrometry. MOTS-c is a longer peptide containing methionine and tryptophan residues, which can oxidise, so careful storage and checking of the batch certificate matter. This is a research design framing only and not a recommendation for any use.

Handling the two peptides in the laboratory

Both peptides are supplied as lyophilised powder and are handled the same way. Vials are stored cold and protected from light, brought to room temperature before opening and reconstituted with bacteriostatic water added slowly down the side of the vial. The working concentration is calculated from the actual mass on each batch certificate, which matters because the two differ more than threefold in molecular weight: a given mass of SS-31 contains far more molecules than the same mass of MOTS-c.

For studies that compare the two on a molar basis, this difference has to be built into the calculation. Reconstituted solutions are refrigerated, labelled and dated, and a fresh certificate of analysis is checked for each new batch. The storage, reconstitution and certificate guides describe each step.

Research use only

SS-31 and MOTS-c supplied by Vitality Peps are for in vitro laboratory research only. Not medicines, not supplements, not for human or veterinary consumption. Nothing above is instructions for use.